Arctic Therapeutics and the EIC Accelerator: A Dementia Drug Bet

Arctic Therapeutics (ATx), an Icelandic biotech led by CEO and co-founder Ivar Hakonarson, is developing AT-001, an oral drug meant to stop amyloid proteins clumping in the brain. Its EIC project promised a registration trial "for commercialization in Iceland" in hereditary cystatin C amyloid angiopathy (HCCAA), a rare inherited disease, and proof-of-concept studies in Europe "to obtain NDA in familial dementia", as a basis for treating Alzheimer's, according to CORDIS.

The European Innovation Council granted €2,500,000 towards a €3.57 million project from March 2023 to February 2025. The final report says the European Medicines Agency authorised a Phase IIb/III study in HCCAA, which enrolled 15 patients "from the original target cohort of up to 25" by December 2024 and showed no major safety concerns. The company expected "to bring the compound to market in early 2026" and "firmly believes this will result in a market approval in Iceland". By September 2026 it had announced neither trial results nor an approval. In November 2025 it started a Phase IIa study of AT-001 in early Alzheimer's disease, it said.

Where Arctic Therapeutics Stands Now

The Alzheimer's study is a randomised, double-blind, placebo-controlled trial at four sites in Denmark and Iceland, measuring safety, blood biomarkers and brain amyloid. The EMA has granted AT-001 orphan drug designation for HCCAA. In February 2026 ATx enrolled the first patients in a Phase IIa trial of AT-004 for acne, and in July 2026 it co-founded Synaptiq Therapeutics with other investors to develop a drug for 22q11 deletion syndrome, according to the company's announcement.

The Science: Breaking Up Toxic Clumps

HCCAA is caused by a mutation in the gene for cystatin C and leads to brain haemorrhages in young carriers. A phase 2a trial published in JAMA Neurology, co-authored by ATx's founder, tested high-dose N-acetylcysteine in 17 HCCAA carriers from 2019 to 2021 and reported that it was well tolerated and reduced disease biomarkers, according to the company's summary. That study was open-label and not randomised. The report describes AT-001 as a new chemical entity that prevents toxic oligomers from forming.

What the EIC Project Promised, and What CORDIS Shows

The project promised a registration trial leading to commercialisation in Iceland and European proof-of-concept studies. The report documents the authorised trial, completed enrolment below target and preliminary biomarker trends, with full analysis due after the last patient finished 12 months of treatment at the end of 2025. It also describes talks with Roche/Genentech and Merck & Co about partnering. No partnership has been announced. CORDIS lists the project as closed.

1. Registration trial startedDeliveredEMA-authorised.
2. Full enrolmentPartial15 of up to 25.
3. Market approvalNot yetEarly 2026 target passed.
4. European POC studiesStartedAlzheimer's Phase IIa.

The Money

ATx closed a €26.5 million Series A in January 2025, with the EIC Fund, Iceland's Kaldbakur, the Investcorp-backed Sanos Group, Cerebrum DAO, the Lurie Family Foundation and a group led by early Kerecis investors, Drug Discovery World reported. The EIC Fund's share, ATx's cash position and the terms of the Synaptiq deal are not public.

What Cannot Be Checked

Why Europe Should Care

Dementia affects more than 55 million people, and current amyloid-targeting treatments carry "serious, and sometimes fatal side effects", the report says. An oral drug that prevents amyloid aggregation would matter far beyond Iceland. The EIC funded the step meant to prove it in a rare disease first; that proof has not yet been published.

The Verdict

Arctic Therapeutics and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.